Funding for the Inheritance Project of the Qilu School of Traditional Chinese Medicine
Conditions
Interventions
Control group:Acupuncture on bilateral Shenshu (BL23), Dachangshu (BL25), Geshu (BL17), and Ashi points
Treatment Group A:On the basis of the treatment given to the control group, perform bloodletting at Weizhong.
Treatment Group B:After needling, perform bloodletting at Houxi (SI3), Shenmai (BL62), Zusanli (ST36), Dachang (BL25), and Weizhong (BL40) acupoints.
Sponsors
Shandong First Medical University Affiliated Hospital of Neck, Shoulder, Waist, and Leg Pain
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Meet the above criteria for liver stagnation and blood stasis type LDH; 2) Age of subjects between 18 and 70 years old (including 18 and 70), with no specific gender restrictions; 3) Clear consciousness and able to clearly express feelings before and after treatment; 4) Voluntarily agree to participate, with patients required to sign the relevant informed consent form, comply well with TCM treatment, and have complete and verifiable data; 5) In the past month, have not received therapies outside this trial such as hormones, non-steroidal anti-inflammatory drugs, opioid analgesics, or related physical treatments, in order to avoid affecting the final comparative results.
Exclusion criteria
Exclusion criteria: 1) LDH patients who do not meet the inclusion criteria; 2) Patients with severe and persistent conditions who meet the surgical indications, or those who are willing to undergo surgery; 3) Patients with a history of severe liver or kidney diseases, immunometabolic diseases, cardiovascular or cerebrovascular diseases, or those at risk of life-threatening events, as well as patients with poorly controlled serious medical conditions such as diabetes, coronary heart disease, or hypertension; 4) Patients exhibiting systemic infection symptoms such as fever or chills, or local acute inflammatory reactions such as localized heat, redness, or swelling; 5) Female patients who are planning pregnancy, pregnant, or breastfeeding; 6) Patients with skin diseases or other contact-transmissible infectious diseases; 7) Patients with abnormal blood or platelet indicators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| JOA;ODI;Inflammatory factor;fNIRS data; | — |
Countries
China
Contacts
Public ContactLuQi WANG
Graduate School of Shandong First Medical University
Outcome results
None listed